[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.225.194.144. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1976

Progress in the Treatment of Adults With Acute Leukemia: Review of Regimens Containing Cytarabine Studied by the Southwest Oncology Group

Author Affiliations

From the Department of Developmental Therapeutics, University of Texas System Cancer Center M. D. Anderson Hospital and Tumor Institute, Houston. Dr Coltman is now with the Department of Medicine, Department of the Air Force, Wilford Hall USAF Medical Center, Lackland Air Force Base, Tex, and Dr Hewlett, the Department of Hematology and Medical Oncology, Cleveland Clinic.

Arch Intern Med. 1976;136(12):1383-1388. doi:10.1001/archinte.1976.03630120035013
Abstract

For many years the treatment of acute leukemia in adults was a fruitless venture that was discouraging to both patient and physician. Remissions were achieved infrequently and were usually of short duration. However, a few patients remained in complete remission for prolonged periods, serving as a source of encouragement to those investigators who persisted in their attempts to improve the therapy of this disease. During the past decade, two major advances have resulted in substantial improvement in the prognosis of these patients. Consequently, skepticism regarding the value of aggressive treatment of adults with acute leukemia is no longer justified. The first major advance was the discovery of the new antileukemic agents, cytarabine (arabinosyl cytosine) and the anthracycline antibiotics. The second major advance was the introduction of combination chemotherapy.

Initial Evaluation of Cytarabine  The Southwest Oncology Group (SWOG) initiated studies with cytarabine in 1966. The first study evaluated the efficacy of

×